A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies

Inclusion Criteria

Inclusion criteria:

- Adult patients (≥18 years old) with advanced hematological malignancies who have
relapsed after or are refractory to standard therapy, or for which no standard
therapy exists; or, are considered inappropriate candidates for standard therapy

- World Health Organization (WHO) performance status ≤ 2

- Patients must meet protocol-specified hematologic and non-hematologic laboratory
values

- Patients must have adequate liver and renal function

Exclusion criteria:

- Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid

- Peripheral neuropathy ≥ CTCAE grade 2

- Unresolved diarrhea ≥ CTCAE grade 2

- Concurrent severe and/or uncontrolled medical conditions which may compromise
participation in the study, including impaired heart function or clinically
significant heart disease, and impaired gastrointestinal function or disease that may
significantly alter aborption of LBH589

- Female patients who are pregnant or breast feeding

- Patients not willing to use an effective method of birth control

- Patients taking medications specified by the protocol as prohibited for
administration in combination with LBH589

- Patients with another primary malignancy that currently requires active intervention
or is currently clinically significant

Other protocol-defined inclusion/exclusion criteria may apply